Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Syn updates 2026 financial calendar for interim results release

Syn updates 2026 financial calendar for interim results release

ReutersReuters2026/08/19 09:23
  • Syn revised its 2026 financial calendar, moving the Q2 2026 interim results release to Aug. 26, 2026.
  • Investor meeting scheduled for Aug. 27, 2026 at 8:30 a.m. in Reykjavik; no webcast planned.
  • Q4 and full-year 2025 results set for Feb. 26, 2026; annual general meeting slated for March 26, 2026.
  • Q1 2026 results due May 7, 2026; Q3 2026 results due Nov. 5, 2026.
  • Q4 and full-year 2026 results scheduled for Feb. 18, 2027; annual general meeting set for March 19, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syn hf. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190522OMX_____CNEWS_IS_GNW1001258302_is) on August 19, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.

智通财经2026/09/14 01:06
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas